[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610830":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":38,"responsibleParty":55,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Proton chemoradiotherapy",null,"Proton chemoradiotherapy: 69.96 cobalt Gray equivalent (CGE) in 33 fractions",[13],"Radiation: Proton chemoradiotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Photon chemoradiotherapy","Photon chemoradiotherapy: 69.96 Gy in 33 fractions",[18],"Radiation: Photon chemoradiotherapy",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":10},"RADIATION","Concurrent chemoradiotherapy will be delivered using intensity modulated proton therapy, with a total dose of 69.96 CGE administered in 33 fractions.",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":10},"Concurrent chemoradiotherapy will be delivered using photon-based volumetric modulated arc therapy, with a total dose of 69.96 Gy administered in 33 fractions.",[15],[28],{"name":29,"affiliation":5,"role":30},"Rodney Cheng En Hsieh, MD, PhD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Rodney Cheng-En Hsieh, MD, PhD","CONTACT","+886-3-328-1200","7000","rodney445@gmail.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":43,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Chang Gung Memorial Hospital at Linkou","RECRUITING","Taoyuan City","Taiwan","333","TW",{"type":47,"coordinates":48},"Point",[49,50],121.29696,24.99368,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":35,"phoneExt":36,"email":37},"Cheng-En Hsieh, MD, PhD",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Cheng-En Hsieh","Associate Professor","100610830","prospective-immuno-radiomic-profiling-in-nasopharyngeal-carcinoma-treated-with-proton-or-photon-chemoradiotherapy-100610830",false,"NCT07232680","Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy","Integrated Prospective Analysis of Radiomic and Immunologic Signatures in Nasopharyngeal Carcinoma Treated With Proton or Photon Radiotherapy","IMPRINT","Inclusion Criteria:\n\n1. Willingness to provide written informed consent.\n2. Pathologically confirmed diagnosis of nasopharyngeal carcinoma\n3. Age ≥18 years\n4. ECOG performance status 0-1\n5. Patients with AJCC v.9 stage I-III disease who undergo chemoradiotherapy\n6. Adequate bone marrow, liver, and renal function within 4 weeks before study registration\n\n   * Hemoglobin ≥ 9.0 g\u002FdL\n   * Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm3\n   * Platelet count ≥ 50,000\u002FμL\n   * Total bilirubin \\\u003C 2.5 mg\u002FdL\n   * Serum albumin \\>2.8 g\u002FdL\n   * Serum creatinine ≤ 1.5 mg\u002FdL\n\nExclusion Criteria:\n\n1. Presence of distant metastasis\n2. Patients with AJCC v.9 cT1N0M0 disease who undergo radiotherapy alone.\n3. Synchronous or prior invasive malignancy, unless disease-free for at least 2 years.\n4. Prior radiotherapy to the head and neck region\n5. Presence of severe major organ dysfunction\n6. Pregnant women or women of childbearing potential who are unwilling to use medically acceptable contraception.","ALL","18 Years",{"count":70,"type":71},500,"ESTIMATED","OBSERVATIONAL","To prospectively investigate and integrate radiomic and immunologic signatures in patients with nasopharyngeal carcinoma (NPC) treated with either proton or photon radiotherapy, with the aim of identifying biomarkers associated with treatment response, toxicity, and long-term outcomes.",[75,76],"NPC Patients","Nasopharyngeal Cancinoma (NPC)",[78,79,80,81,82,83,84,85,86,87],"NPC","proton radiotherapy","photon radiotherapy","proton beam therapy","IMPT","IMRT","IMAT","chemoradiation","Immune response","Radiomics","2025-11-19",{"date":90,"type":91},"2025-11-24","ACTUAL",{"date":93,"type":91},"2025-11-20",{"date":95,"type":71},"2034-08-15",{"name":57,"class":6},1]